Caitlin Cronin

You called out on the last earnings call that Foot & Ankle was softer last year. What did you see in Q1? And have you launched the Incompass Total Ankle

just some more color on Triathlon Gold and if that has launched already

any update on the percentage of hips, knees, shoulders, flowing through the AC channel for you guys

Are you guys seeing any pressure from the competitor launches in hips?

I think you called that out earlier being strong. Was that related to key guidance and maybe the momentum in the financial portion of the enabling tech portfolio?

I think you noted earlier in the call that the tuck-in acquisitions you made last year were going well. Just any more color on those?

You didn't really mention Foot & Ankle in the commentary. How did that business fare in Q4? And any commentary on the market environment going into 2025?

have you seen any momentum, increased interest from hospitals and ASC about the excitement of just having one-stop shop for the Mako solution

Any updated color on the launch and when will move to a broader launch

how do you see ASCs as a part of your revantular strategy? And where did you end the year with ASC penetration

You received clearance for your Iodine Technology in hips recently in Japan, and then, also announced the FDA granted the Technology Breakthrough Device designation in the U.S.

if you could comment on robotic placements in this quarter specifically and then just the pipeline for the rest of the year

any kind of early news there, and kind of updates on the timeline for the integration